Parkinsons 2023 | Parkinsons and Movement Disorders

Theme: Scientific Methodologies and Current Therapeutic approaches for Parkinsons and Movement Disorders

Parkinsons Congress-2023

Parkinsons Congress-2023

Parkinson's 2023 happy to invite you all!!

We take great pride in our world-renowned global event and delighted to welcome all attendees to our “7^th International Conference on Parkinson’s and Movement Disorders” scheduled during June 12-13, 2023 as Webinar. This conference will provide new ideas, convictions, strategies, and tactics in an environment where no other conference will provide an impressive roaster of Keynote speakers, quality attendees, and compelling content. The various thematic sessions will be discussed at this conference, and we welcome you all to attend.

Parkinsons Congress-2023 encourage participants from all top academic institutions and clinical research labs to share their research on all facets of this quickly expanding subject, meet with top researchers, and display the most recent methods. This conference will primarily concentrate on the most recent and exciting advancements in Parkinson's research and it will increase the opportunity for experts from around the world to interact scientifically.

Parkinson's 2023 is an annual gathering of Neurologists, Neurosurgeons Psychiatrists, Research Scholars, to discuss the future of neurological disorders in terms of collaboration and organizational development.

The unprecedented success of our previous conference, as well as the resounding and ginormous responses received, has paved the way for the Parkinsons Congress-2023 Organizing Committee to host the "7^th International Conference on Parkinson’s and Movement Disorders," which will be held on June 12-13, 2023 as Webinar

Parkinsons Congress-2023 is your best opportunity to attend the world's largest gathering of people to join, give lectures, share experiences, and network with present and future scientists to gain knowledge more about in the field of neurology, neuroscience, the central nervous system, neuropharmacology, and neurodegenerative diseases, and to make a significant impact.

A diverse group of experts in the fields of neuroscience, neurology, and neurosurgery could use this year's conference, which has the innovative theme "Scientific Methodologies and Current Therapeutic approaches for Parkinsons and Movement Disorders".

The mission of the Parkinsons Congress-2023 conference is to enhance Parkinson's disease treatments, expedite the interpretation of front-line disclosure at the clinical level, and advance global logical collaboration, discussion, and commerce.

Track 1: Psychology and Psychiatry

Psychiatry is that the branch of drugs targeted on the diagnosing, treatment and interference of mental, emotional and activity disorders. A shrink could be a medical doctor UN agency makes a speciality of psychological state, together with substance use disorders. Psychiatrist’s area unit qualified to assess each the mental and physical aspects of psychological issues.

The 3 main variations between psychiatrists and psychologists are:

Psychiatrists area unit medical doctors, psychologists don't seem to be
Psychiatrists bring down medication, psychologists cannot
Psychiatrists diagnose health problem, manage treatment and supply a variety of therapies for advanced and heavy mental disease. Psychologists specialize in providing psychotherapy to assist patients

Track 2: Parkinson Disease

Parkinson's affliction is a dynamic issue of the sensory system that influences advancement. It develops gradually, at times starting with a barely distinguishable tremor in just a single hand. In any case, while a tremor may be the most surely understood indication of Parkinson's infection, the turmoil in like manner frequently causes strength or directing of advancement. In the early periods of Parkinson's disease, your face may demonstrate beside zero demeanours, or your arms may not swing when you walk. Your discourse may end up being fragile or slurred. Parkinson's disease signs compound as your condition propels after some time.

Drug-induced Parkinsonism
Multiple System Atrophy (MSA)
Progressive Supranuclear Palsy (PSP)
Corticobasal Syndrome (CBS)
Dementia with Lewy bodies (DLB)
Vascular Parkinsonism (VP)

Track 3: Movement Disorders

Movement disorders are clinical syndromes with either an excess of movement or a paucity of voluntary and involuntary movements, unrelated to weakness or spasticity. Movement disorders are synonymous with basal ganglia or extrapyramidal diseases. Movement disorders are conventionally divided into two major categories- hyperkinetic and hypokinetic.

Hyperkinetic movement disorders refer to dyskinesia, or excessive, often repetitive, involuntary movements that intrude upon the normal flow of motor activity.

The common movement disorders include:

Essential Tremor
Restless legs syndrome
Ataxia
Dystonia
Parkinson's Disease
Huntington's Disease
Myoclonus

Track 4: Neurology

Neurology is the division of medicine dealing with the diagnosis and treatment of all classes of conditions and diseases involving the brain, the spinal cord and the peripheral nerves. There are about a hundred billion neurons in the brain, able to produce their own impulses and of getting and transmitting impulses from neighbouring cells. Neurology includes the study of the central nervous system, the peripheral nervous system and the autonomic nervous system.

Some Neurological disorders are:

Headaches
Parkinson's disease
Alzheimer's disease
Acute Spinal Cord Injury
Cerebral Aneurysm
Epilepsy and Seizures
Muscular Dystrophy

Track 5: Neurocognitive Disorders

Neurocognitive disorder is a reduction of cognitive function in one of these areas, especially when physical changes can be seen to have occurred in the cerebrum, for example, after neurological disease, brain injury or drug use. It occurs due to Parkinson Disease with behaviour disturbance. According to the recent projects of the United Nations between 2000 to 2050 the people over 65 years of age will exceed 1.1 billion worldwide. For estimation by 2050 Parkinson’s disease will be $285 billion in the USA.

Some Neurocognitive disorders are:

Alzheimer's disease.
Cerebrovascular disease (Vascular Neurocognitive Disorder)
Frontotemporal Lobar Degeneration (Frontotemporal Neurocognitive Disorder)
Dementia with Lewy Bodies (Neurocognitive Disorder with Lewy Bodies)
Parkinson's disease.
Huntington's disease.
Traumatic Brain Injury

Track 6: Diagnostic and Neuroimaging for Parkinsons Disease

There is no direct treatment for Parkinson’s disease as well any blood test or brain scan that confirms the diagnosis. Most Parkinson’s disease treatments aim to restore the proper of the neurotransmitter acetylcholine and dopamine by increasing the dopamine levels. Treatment is totally based on the medical history and a neurological examination. At present there is no cure for Parkinson’s disease, medications can lessen its symptoms and later stages surgery can be done. Parkinsons in the body; Magnetic resonance imaging (MRI) is a test that produces very clear image of the human body without the use of X-rays. Instead of MRI uses a large magnet, radio waves, and a computer to produce these images. Medications are in three stages- first includes the drug which is known as levodopa which increase the dopamine in the brain, the second set of drugs eases some of the Parkinsons disease symptoms and the third set of drugs helps to control the non-motor symptoms including depression.

Magnetic resonance imaging (MRI)
Single photon emission computed tomography (SPECT)
Positron emission tomography (PET)

Track 7: Neuropharmacology and Neurophysiology

Neuropharmacology is the study of the effects of drugs on the nervous system, with the aim of developing compounds that offer healing benefit in humans with psychiatric and neurological disease. There are two main branches of neuropharmacology which are behavioral and molecular. Behavioral neuropharmacology concentrates on the study of how drugs affect human behavior and how drug dependence and addiction affect the human brain. Molecular neuropharmacology implicates the study of neurons and their neurochemical interactions, with the goal of developing drugs that have suitable effects on neurological function.

Neurophysiology is a division of physiology and neuroscience that studies nervous system function relatively nervous system construction. Neurophysiology aids in the analysis and observing of neurological diseases and it studies relationships between the brain and behavior, especially in the case of individuals with neurological concession. Neurophysiology is associated with the electrophysiology, neuroanatomy, psychology and mathematical neuroscience.

The foremost technologies involved in neurophysiology devices are

Electromyography (EMG)
Electroencephalography (EEG)
Electrocorticography (ECOG)
Evoked Potential (EP)

Track 8: Epidemiology of Parkinsons Disease

Parkinson’s disease is one of the well-known age related neurodegenerative disorder, second in recurrence just to Alzheimer's disease. Parkinson’s disease also causes extensive injury of the motor or sensory pathways extending beyond the pigmental brain stem nuclei. Although the disease symptoms can be controlled by Levodopa but the etiology of the Parkinsons disease remains obscure. In the United States half a million of people are diagnosed as having PD and it is predicted to be triple over next 50 years. PD appears to be slightly more in men than in women usually ranging from 1.2:1 ratio upto 1.5:1. The Parkinsons disease market in US is expected to grow at a rate of 7.3% from sales of $1.1 billion in 2012 to $2.3 billion in 2022. The population with Parkinson’s disease incurred medical expenses of approximately $14.4 per year in United States. In U.S. 15% of people with PD were in the nursing homes as compared to 9 % are of all residents aged 75-84.

Track 9: Alzheimer’s Disease and Dementia

It is a neurodegenerative disease that usually starts slowly and gently degrades over time. Alzheimer's disease is assumed to be caused by the irregular build-up of proteins inside and outside the brain cells. One of the proteins involved is called amyloid, deposits of which form plaques around brain cells. The other protein is called tau, deposits of which form tangles within brain cells. The most common early symptom is struggling in remembering recent actions. As the disease develops, symptoms can include problems with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral issues.

Dementia is a common term for loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with everyday life. The most common cause of dementia is Alzheimer's disease.

Common Symptoms of dementia include:

Memory problems
Asking the same question repeatedly
Difficulty finding or understanding words
Feeling confused in an unfamiliar environment
Anxiety and withdrawal
Mood changes
Personality and behavioral changes
Sleep disturbances

Track 10: Neuromuscular Disorders and Stroke

Neuromuscular disorder is a disease that affects the peripheral nervous system which includes muscles, nerve-muscle junction, and peripheral nerves in the limbs and motor nerve cells in the spinal cord. Approximately 5600 people in the US are diagnosed with ALS each year. In US each year 750,000 people experience stroke, 11000 people suffer spinal cord injury, 500,000 people suffering from cerebral palsy, 270,000 with multiple sclerosis and 5.3 million with the after effects of a traumatic brain injury and amyotrophic lateral sclerosis.

Stroke is the unexpected death of brain cells due to lack of oxygen, affected by blockage of blood flow or breakout of an artery to the brain. Symptoms of stroke can be sudden loss of speech, weakness, or paralysis of one side of the body.

Ischemic Stroke
Transient ischemic attack (TIA)
Thrombotic Stroke
Embolic Stroke
Hemorrhagic Stroke
Subarachnoid Stroke

Track 11: Risk Factors of Parkinson’s Disease

Risk factor for the Parkinsons disease mainly depends on age, hereditary, sex and exposure to toxins. Men are more affected than women; 25%-45% are caused by the loss of dopamine which causes rigid movements. Advancing age is a factor that is more consistently associated with an increase in the Parkinsons disease; only 5%-10% of people get Parkinsons disease before age of 40. It involve some of the symptoms like anxiety, cognitive problems, tremor or shaking, depression, trouble sleeping, low voice, loss of smell etc. Now a day’s Head injury and Gene variation is also a factor for Parkinson’s disease.

Oxidative stress
Advancing age
Turmoil
Motor nerve cells
Stroke
Atherosclerosis
Heredity

Track 12: Neural Transplantation and Neurosurgery

Neural transplantation is the transplantation of nerve cells and tissues into the brain and spinal cord. The cell replacement for Parkinsons Disease is based on two hypothesis- firstly the early symptoms of PD are dependent on the loss of the dopaminergic neurons in the nigrostriatal pathways and secondly the dopaminergic neurons and gathered into dopamine deficient striatum can replace those neurons which has been lost during the disease process and can reverse some extent of the major symptoms of Parkinson disease.

Neurosurgery is the branch of drug that deals with surgery of the nervous system. Utmost people think of neurosurgery as brain surgery but it's much further. It's the medical specialty concerned with the diagnosis and treatment of patients with injury to, or diseases/disorders of the brain, spinal cord and spinal column, and peripheral nerves within all parts of the body. The specialty of neurosurgical care includes both grown-up and Pediatric cases. Dependent upon the nature of the injury or disease a neurological surgeon may give surgical and/ or non-surgical care.

Some Neurosurgery procedures include:

Cerebrovascular- aneurysms and arteriovenous malformations (AVMs), and stroke
Neuro-oncology (brain tumors)
Spinal neurosurgery
Functional and epilepsy neurosurgery
General neurosurgery
Trigeminal neuralgia and nerve compression syndromes
Peripheral nerve injury

Track 13: Molecular Neuroscience and Neurodegeneration

Molecular neuroscience is a branch of neuroscience that observes generalities in molecular biology which is useful to the nervous systems of animals. The scope of this topic includes mechanisms of molecular signaling in the nervous system, molecular neuroanatomy, the effects of genetics and epigenetics on neuronal development, and the molecular basis for neuroplasticity and neurodegenerative diseases. As with molecular biology, molecular neuroscience is a relatively new field that is considerably dynamic.

Neurodegeneration is the continuing loss of structure or function of neurons, including their death. Neurodegenerative disorders usually get worse over time and have no cure. They may be hereditary or be affected by a tumor or stroke. Many neurodegenerative diseases include amyotrophic multiple sclerosis, lateral sclerosis, Parkinson's disease, Alzheimer's disease, Huntington's disease, and prion diseases occur as a result of neurodegenerative processes. Such diseases are incurable, resulting in progressive degeneration of neurons.

Molecular mechanisms of neurodegenerative diseases include:

Excitotoxicity and glutamate receptors
Alzheimer's disease
Parkinson's disease

Track 14: Novel Insights and Therapeutics for Parkinson’s disease

Parkinson’s disease is the essential growth driver of the worldwide Parkinsons disease therapeutics. Most mutations such as SNCA, PINK1, PARK2, PARK7, PLA2G6, FBXO7 and ATP13A2 are the rare cause of the disease and one particular mutation in LRRK2 has been found common in certain populations. The enzymatic function of the mitochondrial localized kinase PINK1 is thereby essential and delivers a fast production of Parkin from its uniform distribution in the cytoplasm to damaged mitochondria. Most people with Parkinson's disease eventually need a medication called levodopa. Levodopa is absorbed by the nerve cells in your brain and turned into the chemical dopamine, which is used to transmit messages between the parts of the brain and nerves that control movement. The therapeutics of Parkinsons Disease includes designing a Clinical trial for Parkinson, Outcome of clinical trials in PSP, therapeutic options for mood, Cognition and Psychosis. Physical therapy cannot cure Parkinson’s disease but therapy can help to compensate the changes brought about by the condition, physical therapy can help with balance problems, fatigue, pain, weakness and sometimes local heat application is produced with high frequency to relieve muscle aches and pain.

Levodopa
Clinical trial for Parkinson,
Outcome of clinical trials in PSP
Therapeutic options for mood
Cognition and Psychosis

Track 15: Managing life with Parkinson’s disease

It is important to develop a solid Parkinson’s disease management plan because Parkinson’s disease is a chronic disease. Managing with Parkinson’s disease includes building a health care team with proper doctors, proper intake of medications, exercises, nutrition and sleep.

Track 16: Neurodermatology

Neurodermatitis is a skin condition which starts with an itchy patch in the skin. This itch-scratch cycle makes the affected skin to convert thick and leathery. It may also progress several itchy spots, mainly on the neck, wrists, forearms, legs or anal region. It is also known as lichen simplex chronicus is not life-threatening or infectious. But the itching can be so penetrating or regular which is disrupts your sleep, sexual function and quality of life.

Symptoms of neurodermatitis include:

An itchy, scaly skin patches
Open sores that bleed
Thick, leathery skin
Discoloured, wrinkled genital skin
Raised, rough patches which are inflamed or darker than the rest of the skin

Track 17: Gene Therapy

It is a technique which aims at treating diseases by genetically modifying population of cells into the patient body instead of using drugs and surgery to prevent from any disorder. Various methods have been developed for the gene delivery to the target cells which includes viral and non-viral systems. It is a creation of producing new cells that will produce a specific neurotransmitter which is dopamine to protect the neural system and then these cells are transplanted to the patient having Parkinsons disease because the neurons cannot be renewed further. Some important reasons are there for focusing gene therapy which includes firstly there is no cure for Parkinson’s disease; secondly some genes which are identified can modulate the neuron phenotype.

Gene therapy clinical trials in PD have focused on:

Restoring dopamine synthesis
Neuroprotection
Genetic neuromodulation
Addressing disease-specific pathogenic variants

Track 18: Paediatric Movement Disorders

Paediatric movement disorder is a moderately new and developing field of child neurology. While hypokinetic scatters, for example, Parkinson disease prevails in adults. There are many genetic disease which cause secondary movement disorders in childhood. Propels in paediatric movement disorder have been made by solidifying movement disorder definitions, growing the range of clinical phenotypes, understanding genetic reasons for movement disorders, and thoroughly assessing treatment adequacy for normal movement disorders. The central nervous systems typically implicated in disorders of movement are the basal and frontal cortex. Five areas were highlighted these advances: consensus definitions, newly found PRRT2 mutation, clinical and genetic range of GLUT-1 lack and neurodegeneration with brain iron aggregation (NBIA) issue, and exhaustive behavioural interventions for tics (CBIT).

Pediatric movement disorders Include:

Tourette syndrome and tic
Tremor
Dystonia
Ataxia
Restless legs syndrome
Myoclonus
Juvenile Huntington disease

Track 19: Mental Health and Mental Disorders

Mental health is important at every stage of life from childhood to old age through maturity. Mental health ncludes emotional, psychological, and social health. It affects how we suppose, sense, and act. It also helps determine how we handle stress, relate to others, and make healthy choices.

Mental disorders or mental illnesses are conditions which affect your thinking, feeling, mood, and behavior. They may be rare or long-lasting. They can affect your ability to relate to others and function every day.

Some common Mental Disorders include:

Clinical depression
Anxiety disorder
Bipolar disorder
Dementia
Attention-deficit/hyperactivity disorder
Schizophrenia
Obsessive compulsive disorder

Market Analysis:

The global Parkinson's disease drugs market size was valued at $5.7 billion in 2021, and is projected to reach $10.4 billion by 2031, growing at a CAGR of 6.2% from 2022 to 2031. Parkinson’s disease also called as idiopathic Parkinsonism and neurodegenerative disease. It is a progressive condition that affects both the neurological system and the bodily components that are under the control of the nervous system. The dopamine is produced in the region of brain is substantia nigra. The dopamine level is decrease in Parkinson’s disease due to substantia cells begin to die in brain.

Increase in demand for Parkinson’s disease drugs is anticipated to increase globally during the forecast period, owing to rise in geriatric population which drive growth of the market. Moreover, an increase in investments by key players toward R&D related to Parkinson’s disease drugs, coupled with rise in geriatric population are some factors further drive growth of the Parkinson's disease drugs industry.

The Parkinson’s disease drugs market size is segmented on the basis of drug class, route of administration, age group and region. On the basis of drug class, the market is classified into decarboxylase inhibitors, dopamine agonists, COMT inhibitors, MAO-B inhibitors and others. On the basis of route of administration, it is segmented into oral, injection and transdermal. On the basis of age group, it is segmented into 50 or below 50 and above 50 years.

The global Parkinson’s disease treatment market size was valued at USD 4.28 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 12.1% from 2022 to 2030. The increasing geriatric population, which is exposed to a high risk of developing Parkinson’s Disease (PD), the high burden of PD in western countries, and the strong product pipeline of disease-modifying therapies are anticipated to be major drivers for the industry. According to the International Parkinson and Movement Disorder Society, in 2020, around 9.4 million individuals had PD worldwide. Moreover, PD affects around 1% of the total population over the age of 60 years, which rises to 5% for the population over the age of 85 years.

Conference Highlights

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date	June 12-13, 2023
Sponsors & Exhibitors	~~Click here for Sponsorship Opportunities~~
Speaker Opportunity Closed
Poster Opportunity Closed	Click Here to View

Useful Links

Special Issues

All accepted abstracts will be published in respective Our International Journals.

Health Care : Current Reviews

Abstracts will be provided with Digital Object Identifier by

7^thInternational Conference on Parkinsons and Movement Disorders June 12-13, 2023 Barcelona, Spain

Recommended Global Healthcare Management Conferences

USA & Americas

Europe & Middle East

Asia Pacific

Meet Inspiring Speakers and Experts at our 1000+ Global Events inclusive of 300+ Conferences, 500+ Workshops and 200+ Symposiums Every year on Medical, Pharma, Engineering, Science, Technology and Business.

For more Conferences visit www.conferenceseries.com

Quick Links

Parkinsons Congress-2023

Conference Highlights

To Collaborate Scientific Professionals around the World

Useful Links

Special Issues